lilly said Monday it will acquire Kelonia Therapeutics for $3. 25 billion upfront in a move aimed at strengthening its oncology and genetic medicines pipeline. The deal centers on Kelonia’s in vivo CAR-T technology and KLN-1010, an investigational one-time intravenous gene therapy designed to generate anti-BCMA CAR-T cells for multiple myeloma. The transaction is expected to close in the second half of 2026, pending regulatory approvals.
What Lilly is getting
The centerpiece of the purchase is Kelonia’s iGPS platform, which Lilly said enables in vivo gene placement using engineered lentiviral particles. That approach is designed to avoid autologous manufacturing, a point that puts the technology at the center of Lilly’s push into a highly targeted cancer treatment space. The lilly move also brings in KLN-1010, which has early Phase 1 results that were presented at the 2025 ASH Annual Meeting.
The structure of the deal signals that Lilly is looking for assets that can expand its reach in both oncology and genetic medicines at the same time. The company framed the acquisition as part of a broader effort to build out its pipeline with newer platforms rather than stand-alone compounds.
lilly’s broader pipeline push
The Kelonia transaction follows other recent steps by Lilly in the same strategic direction. Earlier this year, Lilly agreed to acquire Orna Therapeutics and partnered with Nvidia to advance AI-driven drug discovery. Taken together, those moves point to a company investing in technologies that can reshape how medicines are discovered and developed, not just one program at a time.
For Kelonia, the acquisition closes a startup journey that had already drawn attention because of the promise of in vivo CAR-T. For Lilly, it adds a platform focused on one-time intravenous delivery and anti-BCMA CAR-T generation, both of which fit the company’s push to deepen its cancer pipeline.
What comes next
The next major milestone is regulatory review, which will determine whether the acquisition closes in the second half of 2026. Until then, the lilly-Kelonia deal remains a closely watched test of how far in vivo CAR-T approaches can move from early-stage promise into a larger corporate pipeline. If the transaction clears, Lilly will add another major piece to its oncology and genetic medicines strategy, with lilly continuing to press into a field where platform technology matters as much as any single therapy.
